FinnCap reiterated their under review rating on shares of Dechra Pharmaceuticals plc (LON:DPH) in a report published on Tuesday.

A number of other brokerages have also commented on DPH. Panmure Gordon reissued a buy rating and set a GBX 1,140 ($14.14) price objective on shares of Dechra Pharmaceuticals plc in a report on Sunday, September 11th. Numis Securities Ltd reissued an add rating and set a GBX 1,320 ($16.38) price objective on shares of Dechra Pharmaceuticals plc in a report on Wednesday, August 17th. N+1 Singer decreased their price objective on shares of Dechra Pharmaceuticals plc to GBX 1,350 ($16.75) and set a buy rating on the stock in a report on Friday, September 9th. Jefferies Group reissued a hold rating and set a GBX 1,300 ($16.13) price objective on shares of Dechra Pharmaceuticals plc in a report on Monday, September 5th. Finally, Stifel Nicolaus reissued a hold rating and set a GBX 1,250 ($15.51) price objective on shares of Dechra Pharmaceuticals plc in a report on Monday, September 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of GBX 1,333.86 ($16.55).

Analyst Recommendations for Dechra Pharmaceuticals plc (LON:DPH)

Shares of Dechra Pharmaceuticals plc (LON:DPH) opened at 1282.00 on Tuesday. The firm’s market cap is GBX 1.19 billion. Dechra Pharmaceuticals plc has a 12-month low of GBX 811.00 and a 12-month high of GBX 1,462.00. The stock’s 50 day moving average is GBX 1,326.89 and its 200-day moving average is GBX 1,267.41.

WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/dechra-pharmaceuticals-plcs-dph-under-review-rating-reaffirmed-at-finncap.html.

The company also recently disclosed a dividend, which was paid on Friday, November 18th. Investors of record on Thursday, October 27th were paid a dividend of GBX 12.91 ($0.16) per share. This is a positive change from Dechra Pharmaceuticals plc’s previous dividend of $5.55. The ex-dividend date was Thursday, October 27th. This represents a yield of 0.92%.

Dechra Pharmaceuticals plc Company Profile

Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world. The Company’s segments include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American (NA) Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development.

Receive News & Stock Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related stocks with our FREE daily email newsletter.